Participant registration begins in Phase III clinical trial of Japan’s first recombinant folliitropin alfa/lutropin alfa (FSH/LH) fixed-dose combination – Merck
Merck BioPharma K.K., the Japanese subsidiary of Merck KGaA, began participant registration for a Phase III trial evaluating the efficacy and safety of fixed-dose combinations of follitropin alfa… read more.
